Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium (225Ac) satoreotide tetraxetan
- Development stage
- Unknown
- Lead developer
- Ariceum Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Actinium (225Ac) satoreotide tetraxetan (also known as [225Ac]Ac-DOTA-JR11 or 225Ac-SSO110) is a targeted alpha therapy (TAT) radiopharmaceutical consisting of the somatostatin receptor 2 (SSTR2) antagonist peptide satoreotide tetraxetan (DOTA-JR11) radiolabeled with the alpha-emitting radionuclide actinium-225 (225Ac). It is being developed by Ariceum Therapeutics, which acquired the rights to satoreotide from Ipsen. The drug targets SSTR2, which is overexpressed in neuroendocrine tumors (NETs), small cell lung cancer (SCLC), and Merkel cell carcinoma (MCC). Unlike SSTR2 agonists, the antagonist satoreotide binds to a higher number of receptor sites and exhibits longer tumor retention, delivering a highly localized and potent dose of alpha radiation to destroy cancer cells while sparing surrounding healthy tissue. It is currently in Phase I/II clinical development for extensive-stage small cell lung cancer (ES-SCLC) and Merkel cell carcinoma (MCC).
- Other names
- 225Ac-DOTA-JR11225Ac-satoreotide225Ac-satoreotide tetraxetan225Ac-SSO 110225Ac-SSO110[225Ac]Ac-DOTA-JR11[225Ac]Ac-satoreotide tetraxetanactinium (225Ac) satoreotide tetraxetanactinium-225 satoreotide tetraxetanactinium225 satoreotide tetraxetanactinium 225 satoreotide tetraxetansatoreotide tetraxetan
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on actinium (225Ac) satoreotide tetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium (225Ac) satoreotide tetraxetan.